EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers (NCT06223659)
Investigating the Use of EMLA Topical Cream for Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Cutaneous Cancers
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial tests how well EMLA topical cream works in treating pain in patients with skin cancers receiving Technetium 99 injections for a lymphoscintigraphy mapping procedure. A lymphoscintigraphy mapping procedure is used to find the main or lead lymph node (tissue that fight infection) so it can be removed and checked for tumor cells. Using lymphoscintigraphy to highlight and then surgically remove lymph nodes is standard way to treat skin cancer for many patients. The Technetium 99 injections used for lymphoscintigraphy can be briefly painful due to the sensitivity of the nerve endings in the skin. The EMLA topical cream, which contains a numbing medicine to block pain from nerve endings, has been studied in breast cancer patients with a difference in pain reported, but this is the first time it has been studied in patients undergoing lymphoscintigraphy for skin cancer. This study may help researchers learn whether the use of EMLA cream may improve the associated pain at the time of the lymphoscintigraphy procedure.
Who can join: Review the eligibility criteria below.
Location: Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (800) 293-5066
Email: OSUCCCClinicaltrials@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cutaneous Melanoma
- Neoadjuvant Atezolizumab in Cutaneous Melanoma — Houston, Texas
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma — Boston, Massachusetts
- Exercise to Boost Response to Checkpoint Blockade Immunotherapy — Orlando, Florida
- Exercise to Boost Response to Checkpoint Blockade Immunotherapy — Tampa, Florida
- A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients — Pittsburgh, Pennsylvania
- Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma — San Francisco, California
Explore by condition: All Cutaneous Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.